Kornimate/medical-research-clean huggingface dataset:
evaluation of the metabolic surgery technique for glycemic improvement in type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Obesity

Summary: surgery is one of the management options for type 2 diabetes in patients with moderate obesity. this is a recent option because it has been part of the recommendations since october 2022. the possible surgical techniques are the same as those for bariatric surgery: * sleeve, * bypass, * gastric band, but the main goal is not weight loss, it is remission of type 2 diabetes. it is called metabolic surgery. the ring technique (gastroplasty) is practiced less and less in france because it is less effective in weight loss and is responsible for major discomfort. currently, metabolic surgery is one of the recommendations but no study has compared the effectiveness of the techniques with each other. one or other of the techniques can be chosen according to the preferences of the surgeon, the patient, the center, etc. but this choice is not made objectively, in the absence of comparative data. this study would like to follow up on patients for whom metabolic surgery has been proposed by the doctor,. if the surgery is accepted, this study would like to improve knowledge of the effectiveness of the different techniques, and thus demonstrate which metabolic surgery technique is preferred in terms of effectiveness and safety.


Eligibility criteria:
inclusion criteria: * adult patient and ≤ 65 years old * t2d patient, with individualized glycemic objectives not achieved, despite medical care, in particular diabetological and nutritional, also including adapted physical activity, well conducted according to current good practice recommendations, for at least twelve months * bmi between 30 and 34.9 kg/m² * patient well informed beforehand about metabolic surgery and the study * multidisciplinary evaluation (including a diabetologist) and decision on medical treatment by cm (date prior to inclusion) * medical assessment of an acceptable surgical risk * patient affiliated to or beneficiary of a social security system * patient having freely signed the written informed consent exclusion criteria: * severe cognitive or mental disorders * severe and unstabilized eating behavior disorders * dependence on alcohol and licit and illicit psychoactive substances * illnesses endangering life in the short and medium term * contraindications to general anesthesia * absence of identified prior medical care and foreseeable inability of the patient to participate in lifelong medical monitoring * history of bariatric surgery * pregnant or breastfeeding woman, or having a very long-term pregnancy plan short term (\&lt; 2 years) * adult patient under guardianship or curatorship * patient deprived of liberty or under judicial decision
neurological outcomes following carpal tunnel wound-closure techniques

Conditions: Carpal Tunnel Syndrome Bilateral

Summary: single-centre randomised prospective trial will conducted at the university hospital of split in croatia. the investigators plan to enrol 100 patients, randomly assigned to suture-based wound closure (n=50) or tissue adhesive-based wound closure (n=50) with two-component skin adhesive glubran tiss 2®. the neurological outcomes will assessed postoperatively during the follow-up period at intervals of 2, 6, and 12 weeks respectively.

all surgical procedures will be performed with a tourniquet and local anaesthesia using 2% lidocaine in the palmar soft tissues and carpal tunnel. for all subjects, the standard carpal canal decompression procedure will began withskin incision in the radial half of the palm, followed by carpal ligament transection and cutting. following primary closure, two different techniques were used depending on the subject's randomization group: 1. the skin will be stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0. 2. after subcutaneous stitches with 4-0 coated vicryltm plus ps-2, 3/8 ; a two-component skin adhesive, glubran tiss 2® will be applied. each subject will received 0.35 ml of glubran tiss® in the open wound, and before bandaging, subjects rested for 20 seconds for a polymerization process. the neurological outcomes will assessed postoperatively during the follow-up period at intervals of 2, 6, and 12 weeks respectively.

Eligibility criteria:
inclusion criteria: (all of the above) * age \>18 years * carpal tunnel syndrome * weakness of thumb abduction * with atrophy of the thenar * median nerve conduction impairment estimated by electromyography exclusion criteria: (one or more) * threatening haemorrhagic complications (patients with peroral anticoagulation and/or antithrombotic therapy) * previous wrist trauma or surgery on the wrist region * another aetiology of neuropathy * previous allergic reactions (with lidocaine, cyanoacrylate, formaldehyde, tapes, or adhesives) * personal or family history of keloids or hypertrophic scars * severe general illness with cachexia
achieving better control for older adults with asthma

Conditions: Asthma; Elderly

Summary: asthma in older adults has been overlooked, understudied, and inadequately treated. while asthma programs targeting the unique needs of children, teenagers, women, minorities, and other populations have been successfully developed, there are currently none for older adults. this is particularly distressing as the asthma hospitalization rates, mortality rates, quality of life, and control are significantly worse in the elderly as compared to other age groups. it is clear that novel approaches are needed to improve the care in this population. the investigators group has been active in the research of asthma in the elderly. the investigators have analyzed national asthma data sets to look for disparities in older adults, have conducted qualitative research to determine factors associated with poor control in the elderly, and have performed a pilot study of a self-regulation intervention which was able to improve outcomes. the investigators also have over 20 years of experience in asthma self-regulation interventions and physician communication enhancement for multiple populations of asthma patients. the investigators will combine these strengths into their current protocol. the intervention program will be based on the self-regulation theory of behavior, which will enhance the participants' ability to self-manage this chronic condition, actively involve the participant in their own health care management, and produce sustained results. in this proposal, the investigators will evaluate a self-regulation asthma intervention in a diverse population of older adults. the intervention will be personalized to the challenges and goals each individual faces, which will enhance its applicability in different populations. this intervention will incorporate standard asthma education, complementary techniques for which older adults have expressed a strong interest, and enhanced communication with each participant's physician. asthma specific outcomes will be assessed at 1, 6, and 12 months. the primary goal of this intervention is to decrease health care utilization (emergency department, urgent care, hospital, and unscheduled visits) for older adults with asthma. the investigators will also assess the ability to improve quality of life, asthma symptoms, asthma control, lung function parameters, self-efficacy, and cost effectiveness.


Eligibility criteria:
inclusion criteria: * above the age of 55 * persistent asthma, * have a primary care physician (pcp) who is willing to receive email communication during the study. exclusion criteria: * any other significant cardiopulmonary disease (including chronic obstructive pulmonary disease) * a greater than 20 pack-year smoking history * lack of telephone access * decreased cognitive capacity such that participation in the program would not be possible

Keywords: asthma older adults elderly behavior
diagnostic accuracy of endocytoscopy for superficial esophageal neoplasia

Conditions: Esophageal Cancer, Squamous Cell

Summary: in recent years, endocytoscopy (ec) has undergone rapid development as an advanced endoscopic technique. characterized by real-time histological imaging and detection capabilities, ec enables visualization of living cells in the digestive mucosal layer through methylene blue staining via the endoscopic instrument channel. this technology provides ultra-magnified endocytoscopic images, allowing for identification of key cellular features including epithelial cell morphology and the shape of methylene blue-stained epithelial nuclei, thereby facilitating clear in vivo observation of microstructural characteristics in mucosal tissues - a technique commonly referred to as "optical biopsy". however, current clinical application of ec in china remains limited due to insufficient practical experience and the absence of standardized diagnostic criteria for image interpretation. this study aims to comprehensively evaluate the diagnostic accuracy of domestically developed high-magnification electronic upper gastrointestinal endoscopy for esophageal carcinoma and precancerous lesions, using histopathology as the gold standard. the research objectives include establishing standardized diagnostic evaluation protocols and clarifying the clinical value of this technology through systematic validation.


Eligibility criteria:
inclusion criteria: 1.patients diagnosed with superficial esophageal squamous cell carcinoma or high-grade intraepithelial neoplasia (hgin) through endoscopic and pathological biopsy examinations, scheduled for endoscopic submucosal dissection (esd); 2.patients with esophageal squamous low-grade intraepithelial neoplasia (lgin) confirmed by endoscopic and biopsy histopathological examinations within the preceding six months; 3. patients exhibiting esophageal focal lesions detected during painless upper gastrointestinal endoscopy requiring pathological biopsy. exclusion criteria: 1. patients aged \ 80 years; 2. lesions located at the gastroesophageal junction with clinical suspicion of adenocarcinoma or precancerous lesions; 3. patients with contraindications to sedated/anesthetized upper gastrointestinal endoscopy; 4. patients with coagulation disorders; 5. patients with a history of hypersensitivity to relevant medications (including anesthetics or methylene blue); 6. patients presenting dysphagia or gastrointestinal obstructive symptoms, or those with suspected/confirmed digestive tract obstruction, stenosis, or fistulae; 7. patients declining to provide informed consent for study participation, or any other circumstances deemed by investigators to preclude eligibility.

Keywords: endocytoscopy esophageal neoplasia precancerous lesions deep learning
evaluation of the efficacy of the combination of axitinib with pemetrexed and cisplatin in the treatment of non-squamous non-small cell lung cancer

Conditions: Carcinoma, Non-Small Cell Lung

Summary: ag-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of adeno-, large cell or bronchioalveolar non-small cell lung cancer * cytologic specimens for diagnosis or for cell type classification must have been obtained from bronchial brushings or washings or from needle aspiration of a defined lesion. sputum cytology alone will not be acceptable for diagnosis or for cell type classification. * patients with mixed nsclc with predominantly squamous cell carcinoma should be classified as squamous and thus do not qualify for this study. * stage iiib with malignant effusion (with cytologic confirmation of malignant pleural or pericardial effusion), stage iv, or recurrent disease after definitive loco-regional therapy. * candidate for primary treatment with cisplatin and pemetrexed exclusion criteria: * any histological/cytological evidence of predominantly squamous nsclc. * small cell or carcinoid lung cancer patients are also ineligible. * nsclc that cannot be classified as one of the eligible histologies (adenocarcinoma, large cell or bronchioalveolar). * prior systemic therapy for stage iiib (with malignant effusion), stage iv, or recurrent nsclc. (prior treatment with systemic therapy as adjuvant chemotherapy or in conjunction with radiotherapy for stage ii or iii nsclc is permitted if the last dose of chemotherapy was completed 12 months or more prior to randomization). * prior treatment with a vegf or vegfr inhibitor.

Keywords: non-squamous nsclc axitinib pemetrexed/cisplatin
locoregional surgery of the primary tumor in de novo stage iv breast cancer patients

Conditions: Breast Neoplasm Female; Surgery; Advanced Breast Cancer

Summary: current guidelines lack definitive evidences about the relative benefits of locoregional surgery for the primary tumor in de novo stage iv breast cancer. the aim of this study (sysbtc-001) was to investigate the role of locoregional surgery for primary tumor in de novo stage iv breast cancer.


Eligibility criteria:
inclusion criteria: * operable stage iv breast cancer patients,whose primary lesion is invasive breast cancer confirmed by pathology, and metastases can be confirmed by pathology or imageology examination. * ecog-ps 0-2. * bone marrow, liver and kidney should be fully functional. * patients received the locoregional surgery of the primary tumor in de novo in our center, or didn't received the locoregional surgery of the primary tumor in de novo. * for the patient who accepted systematic treatment before operation, the systematic treatment must be administered within a year since diagnosed. exclusion criteria: * accompanied with other primary malignant tumors. * patients who can't plan for follow-up effectively and regularly. * multiple liver metastasis and alt/ast four times higher than normal at patients' first diagnosis.

Keywords: breast neoplasm female locoregional surgery in de novo stage iv brest cancer overall survival locoregional progression free survival distant progression free survival
a six-month safety and antiviral study in hiv-1 seropositive, azt-experienced patients with cd4 counts less than or equal to 50 cells/mm3 to evaluate mk-639 alone versus zidovudine (azt) and 3tc versus the combination of mk-639 with azt/3tc

Conditions: HIV Infections

Summary: to compare effects on cd4 counts and serum viral rna among hiv-seropositive, zidovudine (azt)-experienced patients in three treatment arms: indinavir sulfate ( mk-639; crixivan ) plus azt plus lamivudine ( 3tc ) versus mk-639 alone versus azt/3tc.

azt-experienced patients are randomized to receive mk-639/azt/3tc or mk-639 alone or azt/3tc. additionally, patients who have received \< 6 months of azt or who are intolerant but received prior 3tc or who require concomitant rifampin therapy may receive open-label mk-639.

Eligibility criteria:
inclusion criteria concurrent medication: allowed for all patients: * standard prophylaxis for opportunistic infections. * continuation of treatment for opportunistic infection. allowed for open-label study patients: * rifampin. patients must have: * hiv positivity. * cd4 count \<= 50 cells/mm3. * more than 6 months of prior azt (blinded study only). note: * patients on the open-label study must have azt intolerance or have \< 6 months of prior azt. prior medication: required for blinded study patients: * \> 6 months of prior azt. required for open-label study patients: * \< 6 months of prior azt. allowed for open-label study patients: * prior 3tc. exclusion criteria concurrent medication: excluded in all patients: * immunosuppressants. excluded in blinded study patients: * azt, ddi, ddc, or d4t. * rifampin. excluded in open-label study patients: * 3tc. prior medication: excluded in all patients: * prior protease inhibitors. * investigational agents and immunomodulators within 30 days prior to study entry. * immunosuppressants within 2 weeks prior to study entry. excluded in blinded study patients: * any prior 3tc. * azt, ddi, ddc, or d4t within 2 weeks prior to study entry. excluded in open-label study patients: 3tc within 30 days prior to study entry.

Keywords: drug therapy, combination acquired immunodeficiency syndrome antiviral agents zidovudine hiv protease inhibitors lamivudine indinavir
quality of life in patients with bladder cancer

Conditions: Bladder Cancer

Summary: the purpose of this study is to learn about the quality of life of people living with bladder cancer. we are interested in learning about how the treatments for bladder cancer affect people. we plan to use the findings from this study to help doctors provide better care and information to patients with bladder cancer.


Eligibility criteria:
inclusion criteria: * all patients (male and female) who are diagnosed with bladder cancer * patients must be scheduled for radical cystectomy and urinary diversion are and/or being evaluated for neo-adjuvant chemotherapy prior to a planned cystectomy. * participants must be able to speak english. * participants must be able to provide informed consent. * participants must be 18 years of age or older to enroll. * participant may be eligible for and may receive neoadjuvant or adjuvant chemotherapy. * participant may have had intravesicle chemotherapy or immunotherapy (bcg, interferon). exclusion criteria: * subjects may be excluded from the study based on the following criteria: * follow-up care not obtained at mskcc. * metastatic disease at diagnosis.

Keywords: quality of life questionnaires 08-076
pre-warmed intravenous fluids and monitored anesthesia care

Conditions: Hypothermia

Summary: the aim of the study is to compare effect of pre-warmed intravenous fluids on the early outcomes in ambulatory patients undergoing monitored anesthesia care.

monitored anesthesia care (mac) has been increasing in fast track anesthesia for ambulatory or outpatient surgery. mac provides lower anesthetic agents than general anesthesia, however it has been shown to result high anesthetic complication rate because of negligent monitoring. therefore, aim of this study is to investigate the effect of pre-warmed intravenous fluids on the core body temperature and the early outcomes.

Eligibility criteria:
inclusion criteria: * 20years to 70years old female patients undergoing urinary incontinence surgery under monitored anesthesia care. exclusion criteria: * preoperative tympanic membrane temperature \>38 or \< 36 * end stage heart failure or renal failure * otitis media

Keywords: prewarmed fluid monitored anesthesia care core body temperature anesthetic satisfaction
research study in healthy volunteers of patients with fanconi anemia, myeloproliferative disorders, or myeloma

Conditions: Chronic Myeloproliferative Disorders; Fanconi Anemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic/Myeloproliferative Neoplasms

Summary: rationale: analyzing tissue and blood samples from healthy volunteers or patients with fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn more about the causes of blood cancers. purpose: the purpose of this study is to analyze in the laboratory blood and bone marrow cells from healthy volunteers or patients with fanconi anemia, myeloproliferative disorders, or myeloma.

objectives: * identify the specific molecular function of the fanconi anemia (fa) complementing gene products in hematopoietic progenitor cells from patients and normal volunteers. * identify functional defects in hematopoietic stromal cells, including macrophages, from patients with fa, and selected blood cancers as well as normal volunteers. outline: peripheral blood mononuclear leukocytes, skin fibroblasts, and marrow fibroblasts are collected for loss-of-function and gain-of-function analysis related to the fanconi anemia complementing gene.

Eligibility criteria:
disease characteristics: * meets 1 of the following criteria: * diagnosis of one of the following: * fanconi's anemia requiring bone marrow biopsy as part of standard care (adults and children) * myeloproliferative disorder or myeloma (adults) * healthy volunteer, meeting 1 of the following criteria: * over 18 years of age * bone marrow transplant donor (children) patient characteristics: * hemoglobin \> 13 g/dl * white blood cells (wbc) \> 4,000/mm³ * platelet count \> 150,000/mm³ * no clinical signs or symptoms of acute or subacute infections (viral, bacterial, or fungal) * no known blood abnormality (healthy volunteers) * no allergies to lidocaine or xylocaine prior concurrent therapy: * not specified

Keywords: fanconi anemia multiple myeloma and other plasma cell neoplasms chronic myeloproliferative disorders myelodysplastic/myeloproliferative neoplasms
the effect of exercise on amateur american football players

Conditions: Athletic Injuries

Summary: football is a team activity that calls for numerous sophisticated talents, including speed, endurance, speed, strength, and quickness. it is getting more and more popular among professional and amateur players, particularly in america.

current research demonstrates that characteristics of american football players like body composition, sprint performance, metabolism, and strength are influenced by elements like the league played, training history, and position played. the ability to generate power with both the upper and lower bodies, change direction quickly, accelerate quickly in both positive and negative directions, run quickly, engage in high-intensity collisions repeatedly, and maintain muscular strength endurance are all skills that players on the court may need.

Eligibility criteria:
inclusion criteria: * male individuals between the ages of 18-25 * being an american football player * regular attendance at training sessions exclusion criteria: * known neurological disorder * serious orthopedic disorders that will prevent him from exercising * cognitive impairment